Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
To investigate the safety, efficacy, pharmacokinetics, and pharmacodynamics of SHR-2173 injection in patients with primary membranous nephropathy
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Age 18-75 years, regardless of gender;
• Weight ≥40.0 kg at screening;
• Diagnosed as primary membranous nephropathy through kidney biopsy.
Locations
Other Locations
China
General hospital of eastern theater command
RECRUITING
Nanjing
Contact Information
Primary
Zhe Zhang
zhe.zhang@hengrui.com
+0518-81220121
Time Frame
Start Date: 2025-12-31
Estimated Completion Date: 2027-09
Participants
Target number of participants: 75
Treatments
Experimental: Treatment group A
Experimental: Treatment group B
Experimental: Treatment group C
Related Therapeutic Areas
Sponsors
Leads: Guangdong Hengrui Pharmaceutical Co., Ltd